VRC (Vaccine Research Center) News Releases

HIV Vaccine Elicits Antibodies in Animals that Neutralize Dozens of HIV Strains
June 4, 2018

An experimental vaccine regimen based on the structure of a vulnerable site on HIV elicited antibodies in mice, guinea pigs and monkeys that neutralize dozens of HIV strains from around the world. The findings were reported today in the journal Nature Medicine by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and their colleagues. 

NIH Scientists Say Advanced Vaccines Could Limit Future Outbreaks
March 22, 2018

Novel vaccine technologies are critical to improving the public health response to infectious disease threats that continually emerge and re-emerge, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. In a perspective in The Journal of the American Medical Association, the experts highlight innovations that could significantly shorten the typical decades-long vaccine development timeline.

Newly Described Human Antibody Prevents Malaria in Mice
March 19, 2018

Scientists have discovered a human antibody that protected mice from infection with the deadliest malaria parasite, Plasmodium falciparum. The research findings provide the basis for future testing in humans to determine if the antibody can provide short-term protection against malaria, and also may aid in vaccine design. Investigators at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, led the research with colleagues at the Fred Hutchinson Cancer Research Center in Seattle.

Gene-Based Zika Vaccine is Safe and Immunogenic in Healthy Adults
December 4, 2017

Results from two Phase 1 clinical trials show an experimental Zika vaccine developed by government scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is safe and induces an immune response in healthy adults. The findings will be published on Dec. 4 in The Lancet. NIAID is currently leading an international effort to evaluate the investigational vaccine in a Phase 2/2b safety and efficacy trial.

NIH Statement on World AIDS Day 2017
December 1, 2017

Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious DiseasesMaureen M. Goodenow, Ph.D., Director, Office of AIDS Research

Three-in-One Antibody Protects Monkeys from HIV-Like Virus
September 20, 2017

A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived, researchers report in Science today.

Phase 2 Zika Vaccine Trial Begins in U.S., Central and South America
March 31, 2017

Vaccinations have begun in a multi-site Phase 2/2b clinical trial testing an experimental DNA vaccine designed to protect against disease caused by Zika infection. The vaccine was developed by government scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Monkeys Suppress HIV-Like Virus for Extended Period after Dual-Antibody Treatment
March 13, 2017

Giving monkeys two powerful anti-HIV antibodies immediately after infection with an HIV-like virus enabled the immune systems of some of the animals to control the virus long after the antibodies were gone, scientists at the National Institutes of Health and The Rockefeller University have found.  

Investigational Vaccine Protects Cattle from Respiratory Syncytial Virus
March 10, 2017

A novel vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, protected cattle from respiratory syncytial virus (RSV) infection, according to research published online in npj Vaccines on March 8. The research was conducted by a team of experts at NIAID, the Pirbright Institute based in the United Kingdom, and the Institute for Research in Biomedicine in Switzerland.

Experimental Zika Virus DNA Vaccines Protective in Monkeys
September 22, 2016

Two experimental Zika virus DNA vaccines developed by National Institutes of Health (NIH) scientists protected monkeys against Zika infection after two doses, according to a study published in Science. One of those vaccines is being evaluated in a Phase 1 human trial now under way in three U.S. locations to evaluate the vaccine’s safety and ability to generate immune responses in people.

NIH Begins Testing Investigational Zika Vaccine in Humans
August 3, 2016

​The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a clinical trial of a vaccine candidate intended to prevent Zika virus infection. The early-stage study will evaluate the experimental vaccine’s safety and ability to generate an immune system response in participants.

Vaccine Strategy Induces Antibodies that Can Target Multiple Influenza Viruses
July 22, 2016

WHAT: Scientists have identified three types of vaccine-induced antibodies that can neutralize diverse strains of influenza virus that infect humans. The discovery will help guide development of a universal influenza vaccine, according to investigators at the National Institute of Allergy and Infectious Diseases (NIAID), and the National Human Genome Research Institute (NHGRI), both part of the National Institutes of Health (NIH), and collaborators who conducted the research. The findings appear in the July 21st online edition of Cell.

NIH-Led Team Discovers New HIV Vaccine Target
May 12, 2016

A team led by scientists at the National Institutes of Health (NIH) has reported a research trifecta. They discovered a new vulnerable site on HIV for a vaccine to target, a broadly neutralizing antibody that binds to that target site, and how the antibody stops the virus from infecting a cell.

Investigational Malaria Vaccine Protects Healthy U.S. Adults for More than One Year
May 9, 2016

An experimental malaria vaccine protected a small number of healthy, malaria-naïve adults in the United States from infection for more than one year after immunization, according to results from a Phase 1 trial described in the May 9th issue of Nature Medicine.

Experimental Ebola Antibody Protects Monkeys
February 25, 2016

Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and colleagues have discovered that a single monoclonal antibody—a protein that attacks viruses—isolated from a human Ebola virus disease survivor protected non-human primates when given as late as five days after lethal Ebola infection. 

HIV Antibody Infusion Safely Suppresses Virus in Infected People
December 23, 2015

A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report. 

NIH-Sponsored Clinical Trial of Chikungunya Vaccine Opens
November 24, 2015

An experimental vaccine to protect against the mosquito-borne illness chikungunya is being tested in a Phase 2 trial sponsored by the National Institutes of Health.

NIH Launches Initiative to Develop Long-Acting HIV Treatment and Prevention Tools
November 18, 2015

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, launched a major initiative to advance novel approaches to treat and prevent HIV infections based on broadly neutralizing antibodies (bNAbs)

HIV Cure Research: NIH Scientists Create Two-Headed Protein to Deplete HIV Reservoir
October 20, 2015

Scientists at the National Institutes of Health have created a protein that awakens resting immune cells infected with HIV and facilitates their destruction in laboratory studies.

Experimental Aerosol TB Vaccine Protects Monkeys, NIH-Funded Researchers Find
October 16, 2015

Researchers funded by the National Institute of Allergy and Infectious Diseases have developed an investigational aerosol tuberculosis vaccine that induced potent immune responses in a small number of rhesus macaques and protected them against pulmonary infection with Mycobacterium tuberculosis .

HVTN 505 Vaccine Induced Antibodies Nonspecific for HIV
July 30, 2015

A study by researchers helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection despite robustly inducing anti-HIV antibodies: the vaccine stimulated antibodies that recognized HIV as well as microbes commonly found in the intestinal tract. 

Experimental MERS Vaccine Shows Promise in Animal Studies
July 28, 2015

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.

Two Paths Pave Way for Development of a Preventive HIV Vaccine
July 23, 2015

National Institute of Allergy and Infectious Diseases& scientists offer a historical perspective on the search for a safe, effective HIV vaccine and describe how they influence current promising approaches in HIV vaccinology.

NIH-Led Team Advances HIV Vaccine Design with Specially Shaped Protein
June 22, 2015

An HIV vaccine research team led by scientists from the National Institutes of Health has engineered a protein to maintain the particular shape predicted to be most effective at stimulating the immune system to produce powerful antibodies against the virus. 

NIAID-Funded HIV Vaccine Research Generates Key Antibodies in Animal Models
June 18, 2015

​A trio of studies describes advances toward the development of an HIV vaccine. The study teams demonstrated techniques for stimulating animal cells to produce antibodies that either could stop HIV from infecting human cells in the laboratory or had the potential to evolve into such antibodies.

NIH Researchers Develop Database on Healthy Immune System
March 12, 2015

​An extensive database identifying immune traits, such as how immune cell function is regulated at the genetic level in healthy people, is reported by researchers from the National Institutes of Health (NIH) and their collaborators. 

Scientists Report on Trial of Early-Generation Ebola, Marburg Vaccine Candidates
December 23, 2014

Results of an early-stage clinical trial of two experimental vaccines against Ebola and Marburg viruses-the first to be completed in an African country-showed that they were safe and induced immune responses in healthy volunteers. 

NIAID/GSK Experimental Ebola Vaccine Appears Safe, Prompts Immune Response
November 26, 2014

An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a phase 1 clinical trial conducted by researchers from the National Institutes of Health. 

NIH-Supported Scientists Unveil Structure, Dynamics of Key HIV Molecules
October 8, 2014

New research has illuminated the movement and complete structure of the spikes on HIV that the virus uses to bind to the cells it infects.

Rapid and Durable Protection Against Ebola Virus With New Vaccine Regimens
September 7, 2014

One shot of an experimental vaccine made from two Ebola virus gene segments incorporated into a chimpanzee cold virus vector protected all four macaque monkeys exposed to high levels of Ebola virus 5 weeks after inoculation.

NIH to Launch Human Safety Study of Ebola Vaccine Candidate
August 28, 2014

​Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health.

Experimental Chikungunya Vaccine Induces Robust Antibody Response
August 14, 2014

An experimental vaccine to prevent the mosquito-borne viral illness chikungunya elicited neutralizing antibodies in volunteers who participated in an early-stage clinical trial conducted by researchers at the National Institute of Allergy and Infectious Diseases.

NIH-Led Scientists Boost Potential of Passive Immunization Against HIV
August 13, 2014

Scientists are pursuing injections or intravenous infusions of broadly neutralizing HIV antibodies (bNAbs) as a strategy for preventing HIV infection.

Powerful HIV Antibodies May Require Assist from Second Antibody to Develop
July 24, 2014

One strategy for developing a highly effective HIV vaccine is to learn how some HIV-infected people naturally develop antibodies that can stop a high percentage of global HIV strains from infecting human cells in the laboratory. 

Study of Antibody Evolution Charts Course toward HIV Vaccine
March 3, 2014

A scientific team has discovered how the immune system makes a powerful antibody that blocks HIV infection of cells by targeting a site on the virus called V1V2.